What Happened? Shares of medical device company DexCom (NASDAQ:DXCM) jumped 10.9% in the morning session after the company reported strong second-quarter res...
Medical device company DexCom (NASDAQ:DXCM) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 13.1% year on year to $1.31 ...
DexCom (NASDAQ:DXCM) reported second-quarter 2026 revenue growth of 13% from a year earlier, supported by continued demand for continuous glucose monitoring systems, expanding reimbursement access and share gains across several patient groups and markets.
Worldwide revenue totaled $1.31 billion, co
Medical device company DexCom (NASDAQ:DXCM) announced better-than-expected revenue in Q2 CY2026, with sales up 13.1% year on year to $1.31 billion. The compa...
Medical device company DexCom (NASDAQ:DXCM) will be reporting results this Thursday after the bell. Here’s what to look for. DexCom beat analysts’ revenue ex...
A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion o...
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the man...
As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the patient monitoring industry, including DexCom (NASDAQ:DXCM) a...
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptic...
The Nasdaq 100 (^NDX) is where investors find some of the most innovative and disruptive companies shaping the future. A select few continue to execute at a ...
With GLP-1 usage continuing to rise, a group of unlikely beneficiaries is emerging; stocks in the broader health care sector and even in retail could stand out.
